​

Unicycive Therapeutics (UNCY) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

UNCY Stock Rating

Unicycive Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

UNCY Price Target Upside V Benchmarks

TypeNameUpside
StockUnicycive Therapeutics-
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.64$0.64$0.64
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2534---7
May, 2534---7
Apr, 2533---6
Mar, 2533---6
Feb, 2533---6
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 12, 2024H.C. WainwrightBuyBuyhold
Sep 06, 2024BenchmarkSpeculative BuySpeculative Buyhold
Aug 16, 2024H.C. WainwrightBuyBuyhold
May 14, 2024Noble Capital MarketsOutperformOutperformhold
Apr 04, 2024Piper SandlerOverweightinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.20$-1.28$-0.06----
Avg Forecast$-1.10$-1.11$-0.51$-0.21$1.00$1.73$0.83
High Forecast$0.24$0.24$-0.33$1.68$1.66$3.17$3.20
Low Forecast$-4.25$-4.27$-0.80$-1.27$-0.19$0.02$-0.18
Surprise %9.09%15.32%-88.24%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$951.00K$675.00K-----
Avg Forecast$967.33K$491.67K$10.00M$32.49M$321.30M$600.54M$391.76M
High Forecast$3.09M$1.57M$31.98M$93.16M$1.03B$1.92B$1.25B
Low Forecast$59.78K$30.39K$618.03K$1.80M$19.86M$37.12M$24.21M
Surprise %-1.69%37.29%-----

Net Income Forecast

$-150M $-100M $-50M $0 $50M $100M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-18.06M$-30.54M$-37.82M----
Avg Forecast$-27.05M$-31.41M$-13.95M$5.07M$18.02M$39.14M$20.37M
High Forecast$5.94M$5.97M$-8.19M$41.21M$40.81M$77.90M$78.58M
Low Forecast$-104.37M$-104.85M$-19.71M$-31.06M$-4.78M$381.86K$-4.47M
Surprise %-33.23%-2.76%171.16%----

UNCY Forecast FAQ

Is Unicycive Therapeutics stock a buy?

Unicycive Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Unicycive Therapeutics is a favorable investment for most analysts.

What is Unicycive Therapeutics's price target?

Unicycive Therapeutics's price target, set by 4 Wall Street analysts, averages - over the next 12 months. The price target range spans from - at the low end to - at the high end, suggesting a potential 0% change from the previous closing price of $0.64.

How does Unicycive Therapeutics stock forecast compare to its benchmarks?

Unicycive Therapeutics's stock forecast shows a 0% downside, underperforming the average forecast for the healthcare stocks sector (24.81%) and underperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Unicycive Therapeutics over the past three months?

  • June 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Unicycive Therapeutics’s EPS forecast?

Unicycive Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.21, marking a 250.00% increase from the reported $-0.06 in 2024. Estimates for the following years are $1 in 2026, $1.73 in 2027, and $0.83 in 2028.

What is Unicycive Therapeutics’s revenue forecast?

Unicycive Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $32.49M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $321.3M, followed by $600.54M for 2027, and $391.76M for 2028.

What is Unicycive Therapeutics’s net income forecast?

Unicycive Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $5.07M, representing a -113.41% decrease from the reported $-37.824M in 2024. Projections indicate $18.02M in 2026, $39.14M in 2027, and $20.37M in 2028.